Becton, Dickinson and Company (NYSE:BDX) Position Cut by Advisory Services Network LLC

Advisory Services Network LLC lowered its holdings in shares of Becton, Dickinson and Company (NYSE:BDXFree Report) by 2.5% during the 4th quarter, Holdings Channel reports. The fund owned 12,086 shares of the medical instruments supplier’s stock after selling 307 shares during the period. Advisory Services Network LLC’s holdings in Becton, Dickinson and Company were worth $2,947,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors also recently added to or reduced their stakes in the business. Norges Bank acquired a new position in shares of Becton, Dickinson and Company during the fourth quarter valued at $761,798,000. Ontario Teachers Pension Plan Board grew its position in Becton, Dickinson and Company by 242.8% in the 3rd quarter. Ontario Teachers Pension Plan Board now owns 1,783,769 shares of the medical instruments supplier’s stock valued at $461,158,000 after buying an additional 1,263,391 shares in the last quarter. Vanguard Group Inc. increased its stake in Becton, Dickinson and Company by 2.0% during the 3rd quarter. Vanguard Group Inc. now owns 25,927,519 shares of the medical instruments supplier’s stock valued at $6,703,041,000 after buying an additional 516,427 shares during the period. Massachusetts Financial Services Co. MA raised its position in shares of Becton, Dickinson and Company by 11.0% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 5,192,832 shares of the medical instruments supplier’s stock worth $1,342,503,000 after buying an additional 512,566 shares in the last quarter. Finally, Royal Bank of Canada boosted its holdings in shares of Becton, Dickinson and Company by 28.5% in the third quarter. Royal Bank of Canada now owns 2,139,493 shares of the medical instruments supplier’s stock valued at $553,121,000 after acquiring an additional 473,914 shares in the last quarter. Institutional investors and hedge funds own 86.97% of the company’s stock.

Becton, Dickinson and Company Trading Down 0.7 %

Shares of NYSE:BDX opened at $228.79 on Monday. The stock has a market capitalization of $66.12 billion, a price-to-earnings ratio of 50.39, a PEG ratio of 2.00 and a beta of 0.45. Becton, Dickinson and Company has a 1-year low of $228.09 and a 1-year high of $287.32. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.97 and a current ratio of 1.41. The company has a 50 day moving average price of $237.66 and a 200 day moving average price of $238.08.

Becton, Dickinson and Company (NYSE:BDXGet Free Report) last posted its quarterly earnings results on Thursday, May 2nd. The medical instruments supplier reported $3.17 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.97 by $0.20. The company had revenue of $5.05 billion for the quarter, compared to analysts’ expectations of $5.04 billion. Becton, Dickinson and Company had a return on equity of 13.90% and a net margin of 6.76%. The firm’s revenue was up 4.6% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.86 earnings per share. On average, research analysts anticipate that Becton, Dickinson and Company will post 13.03 EPS for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, June 28th. Investors of record on Monday, June 10th will be given a $0.95 dividend. The ex-dividend date is Monday, June 10th. This represents a $3.80 dividend on an annualized basis and a dividend yield of 1.66%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 83.70%.

Insider Buying and Selling

In other Becton, Dickinson and Company news, SVP Thomas J. Spoerel sold 282 shares of the company’s stock in a transaction dated Thursday, March 14th. The shares were sold at an average price of $238.29, for a total transaction of $67,197.78. Following the completion of the sale, the senior vice president now directly owns 2,276 shares of the company’s stock, valued at $542,348.04. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In other news, EVP Roland Goette sold 3,300 shares of the firm’s stock in a transaction on Monday, May 13th. The stock was sold at an average price of $236.70, for a total value of $781,110.00. Following the completion of the sale, the executive vice president now owns 14,608 shares of the company’s stock, valued at $3,457,713.60. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP Thomas J. Spoerel sold 282 shares of the company’s stock in a transaction on Thursday, March 14th. The shares were sold at an average price of $238.29, for a total value of $67,197.78. Following the transaction, the senior vice president now directly owns 2,276 shares in the company, valued at $542,348.04. The disclosure for this sale can be found here. In the last quarter, insiders have sold 8,597 shares of company stock valued at $2,028,786. 0.31% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Separately, Barclays raised their price objective on shares of Becton, Dickinson and Company from $305.00 to $312.00 and gave the company an “overweight” rating in a research note on Monday, May 6th. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $281.40.

Read Our Latest Analysis on Becton, Dickinson and Company

Becton, Dickinson and Company Profile

(Free Report)

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.

Featured Stories

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDXFree Report).

Institutional Ownership by Quarter for Becton, Dickinson and Company (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.